What type of study is this?

This is a Human Clinical Trial study.

What question did this study set out to answer?

To evaluate the efficacy and safety of bispecific CD19/20 CAR-T cell therapy in relapsed or refractory non-Hodgkin lymphoma.

December 8, 2025BloodOpen Access

View Full Paper

Ask AI

Bookmark

Authors

Phase I/II trial shows CAR-T therapy achieves 60% complete response in relapsed B-cell lymphoma, indicating promising safety profile.

To evaluate the efficacy and safety of bispecific CD19/20 CAR-T cell therapy in relapsed or refractory non-Hodgkin lymphoma.
Conducted a Phase I/II open-label, single-arm trial.
Evaluated bispecific CD19/20 CAR-T cell therapy in patients with R/R NHL.
Monitored safety and clinical outcomes including overall response and progression-free survival.
32 patients with R/R NHL, including 27 with DLBCL, received treatment.
Best overall response rate was 77%, with a complete response rate of 60%.
Median progression-free survival was 6.8 months, with a manageable safety profile.

Zheng et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark